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Background: Osteoarthritis (OA) is characterized by inflammation, joint immobility, and pain. Non-pharmacologic
agents modulating pro-inflammatory mediator expression offer considerable promise as safe and effective
treatments for OA. We previously determined the anti-inflammatory effect of an avocado/soybean unsaponifiables
(ASU) and epigallocatechin gallate (EGCG) combination on prostaglandin E2 (PGE2) production and nuclear
factor-kappa B (NF-κB) translocation. The aim of this study was to evaluate the effects of ASU + EGCG on
pro-inflammatory gene expression.
Findings: Articular chondrocytes from carpal joints of mature horses were pre-incubated for 24 hours with control
media alone or ASU (8.3 μg/mL) + EGCG (40 ng/mL), followed by one hour activation with interleukin-1 beta
(IL-1β, 10 ng/mL) and tumor necrosis factor-alpha (TNF-α, 1 ng/mL). Total cellular RNA was isolated and real-time
PCR performed to measure IL-1β, TNF-α, interleukin-6 (IL-6), cyclooxygenase-2 (COX-2), and interleukin-8 (IL-8) gene
expression. Intracellular localization of NF-κB was analyzed by immunohistochemistry and Western blot. Pre-treatment
with ASU + EGCG significantly (P < 0.001) decreased gene expression of IL-1β, TNF-α, IL-6, COX-2, and IL-8 in
cytokine-activated chondrocytes. Western blot and immunostaining confirmed NF-κB translocation inhibition.
Conclusions: We demonstrate that ASU + EGCG inhibits cytokine-induced gene expression of IL-1β, TNF-α, IL-6, COX-2,
and IL-8 through modulation of NF-κB. Our results indicate that the activity of ASU + EGCG affects a wide array of
inflammatory molecules in addition to decreasing PGE2 synthesis in activated chondrocytes. The responsiveness of
chondrocytes to this combination supports its potential utility for the inhibition of joint inflammation.
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Introduction
Osteoarthritis (OA) is a degenerative joint disease charac-
terized by articular cartilage erosion, synovial inflammation,
and subchondral bone alterations resulting in pain and
impaired joint function [1]. There is excess production
of pro-inflammatory mediators such as interleukin-1 beta
(IL-1β), tumor necrosis factor-alpha (TNF-α), interleukin-
6 (IL-6), and interleukin-8 (IL-8) [2]. Cyclooxygenase-2
(COX-2), the enzyme that regulates prostaglandin E2* Correspondence: sownby@nutramaxlabs.com
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reproduction in any medium, provided the or(PGE2) synthesis, is also up-regulated. Current treatments
for OA rely heavily on the use of non-steroidal anti-
inflammatory drugs (NSAIDs). However, concerns regarding
adverse side-effects have prompted a search to identify non-
pharmacologic agents that can inhibit pro-inflammatory
mediator production [3]. Studies show expression of many
genes encoding pro-inflammatory mediators and matrix
degrading enzymes are regulated by the transcription
factor, nuclear factor-kappa B (NF-κB) [4]. Suppression of
the NF-κB activating cascade using non-pharmacologic
agents could effectively down-regulate the expression of
pro-inflammatory mediators [3,4].
Several non-pharmacologic products targeting the NF-κB
transduction pathway and promoting joint health have beenLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Table 1 Primer sequences for real-time PCR
Gene Primer sequences: forward/reverse (5′ to 3′) Reference
COX-2 f ATACCAAAACCGCATTGCCG [18]
COX-2 r TCTAACTCCGCAGCCATTTC
GAPDH f GTTTGTGATGGGCGTGAACC [18]
GAPDH r TTGGCAGCACCAGTAGAAGC
IL-1β f TGTACCTGTCTTGTCCCATGAAAG [19]
IL-1β r GCTTTTCCATTTTCCTCTTTGGGTAA
IL-6 f GAAAAAGACGGATGCTTCCAATCTG [19]
IL-6 r TCCGAAAGACCAGTGGTGATTTT
IL-8 f GCCACACTGCGAAAACTCA [19]
IL-8 r GCACAATAATCTGCACCCACTTTG
TNF-α f AAAGGACATCATGAGCACTGAAAG [20]
TNF-α r GGGCCCCCTGCCTTCT
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unsaponifiables (ASU) which is used in Europe for OA
management [5,6]. ASU suppresses gene expression of
IL-1β, TNF-α, COX-2, and inducible nitric oxide synthase
(iNOS), as well as PGE2 and nitric oxide production in bo-
vine and human joint tissue cells [6,7]. When combined
with other compounds such as glucosamine, chondroitin
sulfate, and pentosan polysulfate, ASU potentiated anti-
inflammatory activity [8,9]. Another compound reported
to have anti-inflammatory activity is epigallocatechin gall-
ate (EGCG). It is the most abundant polyphenol in green
tea and is reported to exhibit a variety of biologic activities
including anti-inflammatory and anti-oxidant [10]. It
has been shown to inhibit inflammatory gene expres-
sion in human chondrocytes and fibroblasts via NF-κB
suppression [11,12].
While EGCG has not been evaluated in vivo for its
potential treatment use in OA, ASU has been assessed in
several studies [6]. In one study, horses with experimentally-
induced OA were treated orally with ASU. Although clinical
signs of pain did not decrease, a disease-modifying effect
was observed in horses receiving ASU when compared to
the placebo group [13]. Christensen et al. (2008) conducted
a review with a meta-analysis of randomized controlled trials
using ASU to treat OA symptoms [14]. They concluded
patients, specifically those with knee OA, may be rec-
ommended to try ASU for approximately three months.
Another in vivo study demonstrated that ASU reduced
the development of early osteoarthritic cartilage and
subchondral bone lesions in a canine OA model, as well
as inhibited iNOS and matrix metalloproteinase (MMP)-13
production [15].
We previously showed that ASU+ EGCG in combination
more effectively decreased PGE2 production than either
compound alone in cytokine-activated equine chondrocytes
[16]. Based on these results, we hypothesize that ASU +
EGCG will significantly decrease pro-inflammatory gene
expression in activated articular chondrocytes.
Materials and methods
Chondrocyte culture and experimental design
Articular cartilage was harvested from radio- and intercar-
pal joints of carpi from three adult mares (8 to 24 years
old), scheduled for euthanasia for reasons unrelated to this
study in compliance with Mississippi State University’s
Institutional Animal Care and Use Committee. Cartilage
was processed to retrieve chondrocytes as previously de-
scribed which were subsequently propagated in monolayer
culture until confluent [16]. All experimental tests were run
in triplicate (n = 3).
Chondrocytes (passage 3 to 5) were seeded onto 6-well
plates (5 × 105 cells/9.5 cm2) or 8-well chamber slides
(1 × 104 cells/0.7 cm2) for 24 h and incubated with control
media alone or the combination of ASU (8.3 μg/mL;NMX1000®; Nutramax Laboratories Veterinary Sciences,
Inc., Edgewood, MD) and EGCG (40 ng/mL; Sigma-
Aldrich, St. Louis, MO) for an additional 24 h. Concen-
trations of ASU and EGCG selected for this study have
been reported to be physiologically relevant and were
based on previous results conducted by our laboratory
[7,16,17]. Following pre-treatment, cultures were incu-
bated with control media alone or activated with human
recombinant cytokines IL-1β (10 ng/mL; R&D Systems,
Minneapolis, MN) and TNF-α (1 ng/mL; Sigma-Aldrich)
for 1 h to measure gene expression by real-time PCR, NF-
κB immunohistochemistry, or Western blot. Earlier studies
have confirmed the combination of IL-1β+TNF-α at these
concentrations to be a potent activator for chondrocytes
from several different species including equine and camel
[8,16]. Following activation, supernatant was removed and
a set of 6-well plates was stored at -80°C for gene ex-
pression analysis while another set was used for nuclear
fractionation. Chamber slides were immunostained to
determine NF-κB translocation and aggrecan and types
I and II collagen as described previously [16].
Total RNA isolation, reverse transcription, and quantitative
real-time PCR
Total cellular RNA was isolated using TRIzol (Invitrogen,
Carlsbad, CA) and followed our previously published proto-
col [7]. RNA quantity and quality were evaluated using
the NanoDrop2000 spectrophotometer (Thermo Fisher
Scientific, St. Louis, MO). Complementary DNA (cDNA)
was prepared utilizing the Advantage RT-for-PCR Kit
(BD Biosciences Clontech, Mountain View, CA).
Oligonucleotide primers used for the detection of
specific equine genes IL-1β, TNF-α, IL-6, COX-2, IL-8,
and GAPDH (housekeeping gene) were obtained from
published studies (Table 1). Real-time PCR was performed
in triplicate [7,16] using the iQ5 Multicolor Real-Time PCR
Detection System (Bio-Rad Laboratories, Hercules, CA).
Ownby et al. Journal of Inflammation 2014, 11:8 Page 3 of 7
http://www.journal-inflammation.com/content/11/1/8Amplification specificity was determined by performing
melt curve analysis to detect non-specific amplification
artifacts. Amplified DNA was purified using the QIAquick
PCR Purification Kit (Qiagen Inc., Frederick, MD), and
sequenced at The Synthesis and Sequencing Facility at
Johns Hopkins University (Baltimore, MD) on an AppliedFigure 1 Representative photomicrographs of chondrocytes
co-immunostained with mono-specific antibodies against type I
and type II collagen. Equine chondrocytes at passage 1 (Panel A)
produced type II collagen (green) with no observable type I collagen (red).
Chondrocytes at passage 3 (Panel B) and passage 5 (Panel C) continued
to readily produce type II collagen with observable type I collagen (red).Biosystems 3730 × l DNA Analyzer. Three independent
experiments using three independent cell lines were con-
ducted and the average from these experiments is shown.
NF-ĸB immunohistochemistry and western blot analysis
Nuclear translocation of NF-κB was monitored by
immunohistochemistry as previously described using aFigure 2 Representative photomicrographs of chondrocytes
immunostained for aggrecan. Equine chondrocytes stained for
aggrecan (green) at passage 1 (Panel A), passage 3 (Panel B), and
passage 5 (Panel C). Note that all chondrocytes continued to
produce aggrecan over cell passages.
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(rabbit anti-NF-κB; Santa Cruz Biotechnology, Santa
Cruz, CA), which we earlier determined to cross-react with
equine and camel chondrocytes [8,16]. System controls
were included which consisted of normal serum to sub-
stitute for the primary specific antibody in which only back-
ground staining was observed. Slides were viewed using a
Nikon Eclipse TE200 inverted fluorescence microscope
(Nikon Instruments, Melville, NY) equipped with a Nikon
Spot Camera (Nikon Instruments).
Nuclear fractions of chondrocytes for Western blot
analysis were collected according to protocol using the
Active Motif Nuclear Extract Kit (Carlsbad, CA). Total
protein (10 μg protein/lane) was separated by 4-15%
Mini-PROTEAN® TGX™ gradient gels (Bio-Rad) and
transferred to polyvinylidene difluoride membranes
(Bio-Rad). Membranes were incubated with rabbitFigure 3 Effect of ASU + EGCG on pro-inflammatory gene expression
of cytokines IL-6, IL-1β, and TNF-α significantly increased following 1 h acti
pre-treated with ASU + EGCG. Gene expression of IL-6 and TNF-α did not d
COX-2 and IL-8 gene expression increased following cytokine activation an
treatment. (*Statistical difference relative to IL-1β + TNF-α, P < 0.001, n = 3).anti-NF-κB antibody (1:3,000; Santa Cruz Biotechnology)
and transferred proteins visualized with secondary
horseradish peroxidase-conjugated goat anti-rabbit IgG
antibody (1:50,000; Santa Cruz Biotechnology) followed
by chemiluminescence detection using ECL Plus™ (GE
Healthcare, Piscataway, NJ).
Statistical analysis
SigmaStat 3.0 Software Version 3.5 was used for data ana-
lysis where results are presented as the mean ± 1 standard
deviation (SD) using one-way analysis of variance (ANOVA).
Tukey post-hoc analysis was performed where differences of
P < 0.05 were considered statistically significant.
Results and discussion
Excess production of pro-inflammatory molecules by
chondrocytes and other joint tissues is considered pivotalin chondrocytes following cytokine activation. (A) Gene expression
vation with IL-1β + TNF-α, and significantly decreased in chondrocytes
ecrease to non-activated control levels in pre-treated chondrocytes. (B)
d decreased by 50% and 60%, respectively with ASU + EGCG pre-
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PGE2 plays a key role in OA as it mediates inflammation
and sensitizes pain fibers in the joint [22]. These pro-
inflammatory mediators are known to be regulated by
NF-κB, prompting efforts to identify agents that can
inhibit activation of the NF-κB pathway [3,23]. It is
thought that this approach could help in relieving joint
inflammation and pain in OA.
ASU and EGCG have both been documented for their
anti-inflammatory activity [7,8,11,12]. Of the two com-
pounds, ASU has been reported to have pro-anabolic
activity and has been used for OA management in both
humans and animals [6,24]. In contrast, EGCG has been re-
ported as an anti-oxidant but not clinically studied for its
effect on OA [6,11]. EGCG is the most abundant green tea
polyphenol and is believed responsible for the benefits
observed with green tea consumption [10,25]. In earlier
experiments, we evaluated the effect of various concentra-
tions of ASU and EGCG alone on PGE2 synthesis by acti-
vated equine chondrocytes. We found that the combination
of the two showed significantly greater inhibitory effect
than either compound alone [16]. The present study aims
to further characterize the effect of ASU and EGCG in
combination at the level of gene expression.Figure 4 Immunolocalization of NF-κB in chondrocytes. Immunofluore
panel: Non-activated cells exhibited strong NF-κB cytoplasmic localization w
activation, chondrocyte nuclei displayed intense fluorescence. Right panel:
staining of NF-κB. Arrows point to nuclei. (B) Western blot: Relatively low le
chondrocytes (Lane 1) with cytokine activation increasing NF-κB nuclear pr
decrease in nuclear NF-κB protein compared to activated controls (Lane 3)Articular cartilage obtained from three adult mares ap-
peared smooth, glassy, and without visible lesions. For this
study, we used equine chondrocytes cultured in monolayer
which is a common in vitro model [7,8]. Cells appeared
healthy and easily proliferated in monolayer with 100% via-
bility. Doubling time for monolayer culture was 3-5 days
for each cell line. Cell phenotype characterization showed
approximately 80-90% of cells continued to produce type II
collagen (Figure 1). In contrast, about 10% produced type
I collagen across passages. All cells continued to produce
aggrecan (Figure 2). Although some variation in pheno-
typic switch was observed by passage 5 with up to 30%
of chondrocytes showing type I collagen production,
most chondrocytes retained many features of the cartil-
age phenotype. Chondrocytes incubated with control
media alone expressed low levels of TNF-α, IL-6, COX-2,
and IL-8 (Figure 3A,B). We measured IL-1β expression
in non-stimulated cells which is similar to other findings
[24]. David et al. (2007) also observed non-stimulated
equine chondrocytes expressing detectable levels of IL-1β.
Cytokine activation increased gene expression of all five in-
flammatory markers compared to non-activated controls
(C). Treatment with ASU+ EGCG significantly (P < 0.001,
n = 3) decreased IL-1β, TNF-α, IL-6, COX-2, and IL-8 genescence of NF-κB was analyzed by immunohistochemistry. (A) Left
hile nuclei remained unstained. Middle panel: Following cytokine
Chondrocytes pre-treated with ASU + EGCG did not show nuclear
vels of NF-κB nuclear protein were expressed in non-activated
otein levels (Lane 2). Cells pre-treated with ASU + EGCG showed a
.
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Gene expression of IL-6 and TNF-α significantly decreased
with ASU+ EGCG pre-treatment, although not back to
non-activated control levels. Through immunostaining
for NF-κB, we observed cytokine, IL-8, and COX-2 in-
hibition was paralleled by NF-κB nuclear translocation
inhibition (Figure 4A). Western blot analysis of nuclear
protein extracts verified NF-κB protein translocation.
Nuclear extracts from IL-1β-stimulated cells showed
an increase in NF-κB protein as indicated by an in-
crease in band intensity (Figure 4B; Lane 2) when com-
pared to nuclear extracts from non-activated cells
(Lane 1). Decreased nuclear NF-κB protein in cells
pre-treated with ASU + EGCG (Lane 3) was indicated
by a decrease in band intensity compared to activated
controls (Figure 4B).
The principal finding is ASU + EGCG down-regulates
an array of pro-inflammatory genes, and that this inhib-
ition is associated with inhibition of NF-κB translocation.
Although a limited number of cell lines were evaluated
(n = 3), the response of equine chondrocytes to cytokine
activation and subsequent inhibition by ASU + EGCG was
consistently similar. Demonstration that ASU + EGCG suc-
cessfully modulates cytokines IL-1β, TNF-α, IL-6, IL-8, as
well as COX-2 illustrates a mode of action different from
that of traditional NSAIDs. Several NSAIDs have been
shown to suppress NF-κB activation [26]; however,
comparisons between the IC50 of NSAIDs against COX
and NF-κB inhibition suggest disparate efficacies. It
has been reported that some NSAIDs, such as carpro-
fen, inhibited inflammatory mediators through add-
itional mechanisms other than NF-κB [26]. These
comparisons have led to the conclusion that some
NSAIDs have COX-independent effects which are me-
diated through inhibition of NF-κB [27]. Results from
this study suggest that the ASU + EGCG combination
may exert a COX-independent effect mediated, at least
in part, through NF-κB inhibition. Gabay et al. (2008)
showed ASU alone to decrease MMP-3 and -13 expres-
sion, PGE2 synthesis, as well as prevent NF-κB nuclear
translocation and inhibit the ERK1/2 signaling pathway
in stressed hyalin chondrocytes [28]. Another study
has shown EGCG to inhibit LPS-induced IκBα degrad-
ation, NF-κB nuclear translocation, and NF-κB DNA
binding activity in bone marrow-derived macrophages
(BMMs) [25]. They also determined that EGCG inhibited
phosphorylation of ERK1/2, JNK, and p38 in BMMs,
thereby further inhibiting the inflammatory cascade.
Although ASU is reported to affect NF-κB, little is
known about its effects on other molecules involved in
the NF-κB signaling pathway. The most important
conclusion to draw from this study is the observation
that the ASU + EGCG combination targets NF-κB, which
regulates inflammatory processes. Therefore, modulationof the NF-κB cell signaling pathway by ASU + EGCG
could be beneficial in managing joint inflammation associ-
ated with OA.
Conclusions
The ASU + EGCG combination demonstrated anti-
inflammatory activity through down-regulation of pro-
inflammatory cytokine and COX-2 expression through
the NF-κB signaling pathway. An approach of using a
non-pharmacologic compound combination, such as
ASU + EGCG, could be a promising strategy for inhibiting
joint inflammation associated with OA.
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